Smithfield Trust CO Neurocrine Biosciences Inc Transaction History
Smithfield Trust CO
- $2.01 Billion
- Q4 2024
A detailed history of Smithfield Trust CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Smithfield Trust CO holds 60 shares of NBIX stock, worth $7,123. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60
Previous 60
-0.0%
Holding current value
$7,123
Previous $6,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding NBIX
# of Institutions
656Shares Held
96.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.68 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.2 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$581 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$358 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$301 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.4B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...